Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal

Shares of Gilead Sciences, Inc. (GILD) were down 10.15% after it announced that the late-stage study evaluating oncology drug Trodelvy (sacituzumab govitecan) in previously treated metastatic non-small cell lung cancer (“NSCLC”) failed.The phase III study, EVOKE-01, evaluated Trodelvy vis-à-vis docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. The study enrolled 603 participants who were randomized equally in ...